This Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) provides $716,587 to Boston Children's Hospital to advance equity in rare disease genomic research. The key objectives are to: Develop and implement a Diversity, Equity, and Inclusion toolkit within the Broad Institute's Rare Genomes Project to improve engagement and participation from historically underrepresented populations in rare disease genomic studies. This will involve...
This federal Cooperative Agreement award for $455,035 was granted on August 15, 2025 by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award, titled "Leading Equitable Research in Alzheimer's Disease in Africa (LEAD Africa)," aims to establish an Alzheimer's disease and related dementias (AD/ADRD) research infrastructure in resource-limited areas of Africa. The project will be executed through a collaboration between research...
This Project Grant award of $193,631 from the Fogarty International Center (CFDA 93.989 - International Research and Research Training) will support the "Scaling Up Advanced Genomics and Bioinformatics Research Training in Pediatric HIV/AIDS in Uganda - SURGE" program. The program aims to increase the pool of highly trained and skilled independent genomics and bioinformatics scientists to conduct research in pediatric HIV in Uganda. Key products and services to be delivered include:...
This $100,000 Project Grant awarded on June 3, 2024 by the U.S. Department of State Bureau of African Affairs under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) Program (CFDA 19.029) will support community-led monitoring to improve healthcare services in Kinshasa, Democratic Republic of the Congo. The prime awardee, Miscellaneous Foreign Awardees (doing business as Federal Egov IAE Initiative - Generic Entity Identifier), will utilize the funding over the 12-month period ending...
This Project Grant award of $1,553,810 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate a genomic surveillance approach for monitoring artemisinin resistance in Plasmodium falciparum malaria in Africa. The project aims to identify genetic mutations and altered biological functions associated with artemisinin resistance, which is a critical concern as resistance emerges...
The Children's Hospital Corporation, doing business as Boston Children's Hospital, received a $2,000 Project Grant award from the National Institutes of Health's John E. Fogarty International Center (CFDA 93.989 - International Research and Research Training) to study ATP1A3-related disorders in Brazil. The key goals of this 2-year project are to: Establish a large patient cohort in Brazil to study the genotype-phenotype correlation and natural history of ATP1A3-related disorders, which...
This Project Grant award in the amount of $431,712, funded by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to improve HIV testing among children under five in rural Uganda. The primary goal is to engage with traditional healers to facilitate HIV counseling and testing via oral swab antigen tests for this vulnerable pediatric population. The award supports two key activities: 1) determining barriers and...
The Project Grant award of $790,989 from the National Institute of Child Health and Human Development's Child Health and Human Development Extramural Research program (CFDA 93.865) is funding research on the palliative care needs of children with rare diseases and their families. The principal investigator will evaluate the Family Centered (FACE) Pediatric Advance Care Planning intervention, which integrates evidence-based approaches to address basic palliative care needs and advance care...
This $131,278 Project Grant awarded by the Fogarty International Center (CFDA 93.989 - International Research and Research Training program) will support the University of Global Health Equity (UGHE) in Rwanda to research and implement decentralized breast biopsy services at district hospitals. The goal is to improve early diagnosis and treatment of breast cancer, a leading cause of cancer mortality in low- and middle-income countries like Rwanda. The 5-year project will build UGHE's capacity in...
This NSF Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Zebramd Inc. aims to develop an electronic health record (EHR) integrated artificial intelligence system capable of predicting rare diseases in undiagnosed patients and providing evidence-based treatment recommendations for already diagnosed rare disease patients. The broader impact of this Small Business Innovation Research (SBIR) Phase I project is to potentially improve the diagnosis and...
AFRICAN RARE DISEASES INITIATIVE (ARDI): ADVANCING GENOMIC MEDICINE THROUGH RARE DISEASES RESEARCH IN AFRICA - PROJECT SUMMARY ABOUT 3.5-5.9% OF THE WORLD POPULATION COULD BE AFFECTED BY A RARE DISEASE, CORRESPONDING PROPORTIONALLY TO 3.79-6.39 MILLION PEOPLE IN THE DEMOCRATIC REPUBLIC OF CONGO (DRC). THE DISTRIBUTION OF RARE DISEASES IS NOT UNIFORM ACROSS COUNTRIES OR SUB-POPULATIONS. THIS UNEVEN DISTRIBUTION SUGGESTS THAT EACH COUNTRY OR REGION SHOULD DETERMINE THE FREQUENCY AND DISTRIBUTION RARE DISEASES WITHIN ITS BORDERS AND DEVELOP A PREVENTION, SCREENING, MANAGEMENT, AND ADVOCACY PLAN. INTERESTINGLY, KNOWLEDGE GENERATED IN ONE COUNTRY OR REGION IS HIGHLY IMPORTANT IN ADVANCING GENOMIC MEDICINE IN OTHER COUNTRIES AS WELL. AFRICAN DATA ARE UNDERREPRESENTED IN THE VAST MAJORITY OF REPUTABLE DATABASES. SINCE THE ABILITY TO MAKE DISCOVERIES INCREASES WITH DATA, THIS PAUCITY OF AFRICAN DATA PREVENTS DISCOVERIES IN AFRICA AND IMPROVEMENT OF DIAGNOSTIC AND CARE FOR RARE DISEASES PATIENTS. BESIDES, AFRICAN COUNTRIES SUCH AS THE DEMOCRATIC REPUBLIC OF CONGO (DRC) ARE IN A VERY GOOD MOMENTUM. FIRST, THE GENOMIC DIVERSITY IS HIGHER IN AFRICA. SECOND, THE TECHNOLOGICAL BARRIERS ARE BEING BROKEN WITH THE ADVENT OF THE CLOUD AND THE DEPLOYMENT OF BIOINFORMATICS TOOLS AND OTHER RESOURCES IN THE CLOUD. THIRD, THE MOBILE INTERNET HAS BEEN BROADLY DEPLOYED IN THE DRC AND OTHER SUB-SAHARAN COUNTRIES, WHICH IS FACILITATING ACCESS TO HIGH COMPUTING RESOURCES IN THE CLOUD AND REMOVING THE NEED FOR HEAVY LOCAL INFRASTRUCTURE OR SENIOR BIOINFORMATICIANS TO CONDUCT BIOINFORMATICS ANALYSIS IN SUB-SAHARAN COUNTRIES. FINALLY, THE EXPERTISE FOR RARE DISEASES GENOMICS HAS INCREASED SIGNIFICANTLY IN DRC, LEADING TO MULTIPLE RESEARCH PROJECTS INVOLVING THE ANALYSIS OF GENOMIC DATA BEING PERFORMED IN THE CENTER FOR HUMAN GENETICS OF THE UNIVERSITY OF KINSHASA. HOWEVER, POOR QUALITY DATA LEADS TO WRONG POLICIES. AN EFFORT STILL NEEDS TO BE MADE IN BUILDING NETWORKS TO INCREASE THE QUALITY AND VOLUME OF DATA. THIS REQUIRES THE HARMONIZATION OF TOOLS AND PROCEDURES FOR DATA COLLECTION AND PROCESSING. THE AFRICAN RARE DISEASES INITIATIVE (ARDI) IS DESIGNED TO BE A MODEL OF HOW A SUB-SAHARAN AFRICAN COUNTRY MAY BECOME READY TO ENTER THE GENOMIC MEDICINE ERA AND MAKE SIGNIFICANT CONTRIBUTIONS TO GLOBAL GENOMIC MEDICINE. WE WILL TAKE ADVANTAGE OF THE OPPORTUNITIES LISTED ABOVE. ONCE THIS PROJECT IS COMPLETED, THE FIRST EXPERT NETWORK FOR RARE DISEASES WILL BE EFFECTIVE IN A SUB-SAHARAN AFRICAN COUNTRY AND CONGOLESE PATIENTS WILL HAVE BEEN DIAGNOSED. THE FIRST MOBILE APP AND ELECTRONIC REGISTRY OF AFRICAN RARE DISEASE PATIENTS WILL BE IMPLEMENTED IN A SUB-SAHARAN AFRICAN COUNTRY. THE FEASIBILITY OF ANALYSIS OF GENOMIC DATA FROM AFRICA IN THE CLOUD WILL BE DEMONSTRATED AT A BROADER SCALE. OUR COLLABORATIONS WITH THE UDNI, THE CLINGEN, THE FDNA, THE BAYLOR COLLEGE OF MEDICINE, AND THE BROAD INSTITUTE WILL OFFER ASSURANCE OF THE QUALITY OF DATA GENERATED IN THIS PROJECT. ON THE SCIENTIFIC FRONT, THE EPIDEMIOLOGY AND UNDERLYING GENETICS OF RARE DISEASES IN AFRICA WILL BE REVEALED. WE WILL USE THE PUBLICATIONS, CLINVAR, DECIPHER AND THE ATLAS OF HUMAN MALFORMATION SYNDROMES IN DIVERSE POPULATIONS TO CONTRIBUTE TO THE GLOBAL GENOMIC MEDICINE COMMUNITY. THE REGISTRY WILL ALLOW MORE DISEASE-SPECIFIC RESEARCH TO BE CONDUCTED. THE MODEL DEVELOPED IN THIS PROJECT IS EXPECTED TO BE TAKEN UP BY THE GOVERNMENT AND BE REPLICATED IN COUNTRIES WITH SIMILAR CHALLENGES.